Aegis Life Revenue and Competitors
Estimated Revenue & Valuation
- Aegis Life's estimated annual revenue is currently $1.2M per year.
- Aegis Life's estimated revenue per employee is $100,500
Employee Data
- Aegis Life has 12 Employees.
- Aegis Life grew their employee count by 9% last year.
Aegis Life's People
Name | Title | Email/Phone |
---|---|---|
1 | Founder / CEO | Reveal Email/Phone |
2 | Founder / Chief Scientific Officer | Reveal Email/Phone |
3 | Chief Manufacturing Officer | Reveal Email/Phone |
4 | VP Clinical Development | Reveal Email/Phone |
5 | Director Antibody Therapeutics | Reveal Email/Phone |
6 | Executive Admin and Operations Manager | Reveal Email/Phone |
Aegis Life Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $84.8M | 422 | 24% | N/A | N/A |
#2 | $0.4M | 2 | 0% | N/A | N/A |
#3 | $32M | 159 | 3% | N/A | N/A |
#4 | $35M | 121 | 3% | $62.5M | N/A |
#5 | $30.2M | 150 | 18% | N/A | N/A |
#6 | $135.3M | 673 | 0% | N/A | N/A |
#7 | $110.3M | 549 | N/A | N/A | N/A |
#8 | $60.1M | 299 | -4% | N/A | N/A |
#9 | $554.8M | 1725 | 2% | N/A | N/A |
#10 | $10.5M | 52 | 4% | N/A | N/A |
What Is Aegis Life?
Aegis Life, Inc. is a biotechnology company founded in early 2020 with a mission to prevent and treat existing, emerging, and future contagions. Our nucleic acid delivery technology Fusogenix PLV stems from more than a decade of research and development in gene delivery. We actively leverage the Fusogenix PLV platform to accelerate the discovery, clinical development, and manufacture of vaccines and therapeutics for infectious diseases.
keywords:N/AN/A
Total Funding
12
Number of Employees
$1.2M
Revenue (est)
9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1M | 12 | 9% | N/A |
#2 | $1M | 12 | N/A | N/A |
#3 | $1M | 12 | N/A | N/A |
#4 | $1.8M | 12 | N/A | N/A |
#5 | $1M | 12 | N/A | N/A |